StockData
ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31

ATOSSA THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.56−0.35 (-12.03%)

Close on Oct 19, 2026

Market cap
$22.81M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 7, 2026Before market open–––
Q4 FY2025
Ended Dec 31, 2025
Jan 9, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025Before market open–$-0.07–
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 25, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open–––
Q2 FY2024
Ended Jun 30, 2024
Aug 12, 2024Before market open–$-0.05–
Q1 FY2024
Ended Mar 31, 2024
Apr 1, 2024After market close–––
Q3 FY2023
Ended Sep 30, 2023
Nov 13, 2023Before market open–$-0.05–
Q2 FY2023
Ended Jun 30, 2023
Aug 14, 2023Before market open–$-0.08–

Press releases

Announcements Atossa Therapeutics filed with the SEC